All articles tagged with #amyloid protein
Originally Published 2 months ago — by WGAL
A Lancaster County family benefits from new FDA-approved Alzheimer's drugs, Leqembi and Kisunla, which target amyloid protein buildup in the brain, offering hope for slowing disease progression and improving quality of life, with local health systems expanding access and research.
Originally Published 2 years ago — by OregonLive
The U.S. FDA has granted traditional approval for Leqembi (lecanemab), a new drug for the treatment of early Alzheimer's disease. Leqembi is a monoclonal antibody that slows the progression of symptoms by targeting the amyloid protein found in the brains of Alzheimer's patients. However, the drug is only indicated for individuals with proven amyloid protein in the brain and early Alzheimer's or mild cognitive impairment. It has shown some success in reducing amyloid protein deposition but has only modestly slowed the progression of the disease. Screening for Alzheimer's with this drug is not a high priority, and other lifestyle interventions such as diet, exercise, and cognitive training may be more beneficial in reducing dementia risk.
Originally Published 2 years ago — by Medical Xpress
Chronic sleep disturbances are an inescapable risk factor for Alzheimer's disease, according to scientists at Washington University School of Medicine in St. Louis, Missouri. The team demonstrated in a series of experiments that sleep deprivation prevents immune cells known as microglia from properly cleaning up deposits of amyloid protein during the sleep cycle, a finding that helps explain the long-observed connection between sleep loss and neurodegeneration. Amyloid proteins are the building blocks of gooey amyloid plaques, a key hallmark of Alzheimer's disease.